Cargando…
Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276344/ https://www.ncbi.nlm.nih.gov/pubmed/34924503 http://dx.doi.org/10.1097/CM9.0000000000001896 |
| _version_ | 1784745702788694016 |
|---|---|
| author | Peng, Yanren Guo, Danxia Jiang, Sijie Zheng, Hua |
| author_facet | Peng, Yanren Guo, Danxia Jiang, Sijie Zheng, Hua |
| author_sort | Peng, Yanren |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9276344 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92763442022-07-13 Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia Peng, Yanren Guo, Danxia Jiang, Sijie Zheng, Hua Chin Med J (Engl) Correspondence Lippincott Williams & Wilkins 2022-03-20 2021-12-16 /pmc/articles/PMC9276344/ /pubmed/34924503 http://dx.doi.org/10.1097/CM9.0000000000001896 Text en Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Correspondence Peng, Yanren Guo, Danxia Jiang, Sijie Zheng, Hua Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia |
| title | Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia |
| title_full | Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia |
| title_fullStr | Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia |
| title_full_unstemmed | Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia |
| title_short | Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia |
| title_sort | application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276344/ https://www.ncbi.nlm.nih.gov/pubmed/34924503 http://dx.doi.org/10.1097/CM9.0000000000001896 |
| work_keys_str_mv | AT pengyanren applicationofproproteinconvertasesubtilisinkexintype9inhibitorevolocumabinpatientswithseverehypertriglyceridemia AT guodanxia applicationofproproteinconvertasesubtilisinkexintype9inhibitorevolocumabinpatientswithseverehypertriglyceridemia AT jiangsijie applicationofproproteinconvertasesubtilisinkexintype9inhibitorevolocumabinpatientswithseverehypertriglyceridemia AT zhenghua applicationofproproteinconvertasesubtilisinkexintype9inhibitorevolocumabinpatientswithseverehypertriglyceridemia |